SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $802,141 | +188.2% | 27,433 | +232.9% | 0.00% | – |
| Q2 2023 | $278,299 | -29.9% | 8,241 | -22.4% | 0.00% | – |
| Q4 2022 | $397,107 | +89.1% | 10,615 | +72.0% | 0.00% | – |
| Q3 2022 | $210,000 | -7.5% | 6,170 | -21.0% | 0.00% | – |
| Q2 2022 | $227,000 | -56.3% | 7,812 | -51.2% | 0.00% | – |
| Q1 2022 | $519,000 | +18.8% | 15,996 | +10.3% | 0.00% | – |
| Q4 2021 | $437,000 | -11.2% | 14,508 | -20.5% | 0.00% | – |
| Q3 2021 | $492,000 | -18.7% | 18,259 | -1.3% | 0.00% | – |
| Q2 2021 | $605,000 | +34.4% | 18,494 | +15.5% | 0.00% | – |
| Q1 2021 | $450,000 | -7.4% | 16,006 | -6.9% | 0.00% | – |
| Q4 2020 | $486,000 | +138.2% | 17,195 | +74.1% | 0.00% | – |
| Q3 2020 | $204,000 | -39.6% | 9,878 | -30.4% | 0.00% | – |
| Q2 2020 | $338,000 | +97.7% | 14,186 | +42.0% | 0.00% | – |
| Q1 2020 | $171,000 | -79.1% | 9,987 | -71.1% | 0.00% | -100.0% |
| Q4 2019 | $819,000 | -22.8% | 34,523 | -10.6% | 0.00% | 0.0% |
| Q3 2019 | $1,061,000 | -22.3% | 38,612 | -6.4% | 0.00% | 0.0% |
| Q2 2019 | $1,366,000 | -2.5% | 41,271 | +3.2% | 0.00% | 0.0% |
| Q1 2019 | $1,401,000 | +0.7% | 39,972 | -4.6% | 0.00% | 0.0% |
| Q4 2018 | $1,391,000 | -35.1% | 41,884 | -1.6% | 0.00% | -50.0% |
| Q3 2018 | $2,142,000 | -55.2% | 42,558 | -46.8% | 0.00% | -50.0% |
| Q2 2018 | $4,783,000 | +176.3% | 79,922 | +111.5% | 0.00% | +100.0% |
| Q1 2018 | $1,731,000 | +9.9% | 37,784 | -4.4% | 0.00% | +100.0% |
| Q4 2017 | $1,575,000 | +1.5% | 39,520 | +1.9% | 0.00% | 0.0% |
| Q3 2017 | $1,552,000 | -23.6% | 38,785 | -17.7% | 0.00% | -50.0% |
| Q2 2017 | $2,032,000 | -4.0% | 47,123 | -30.3% | 0.00% | 0.0% |
| Q1 2017 | $2,117,000 | +21.7% | 67,611 | -16.2% | 0.00% | 0.0% |
| Q4 2016 | $1,739,000 | +732.1% | 80,705 | +854.6% | 0.00% | – |
| Q3 2016 | $209,000 | +5.0% | 8,454 | -13.8% | 0.00% | – |
| Q2 2016 | $199,000 | +8.7% | 9,807 | -18.3% | 0.00% | – |
| Q1 2016 | $183,000 | -33.0% | 12,008 | -41.1% | 0.00% | – |
| Q4 2015 | $273,000 | +16.2% | 20,370 | +21.6% | 0.00% | – |
| Q3 2015 | $235,000 | -17.3% | 16,749 | +0.2% | 0.00% | – |
| Q2 2015 | $284,000 | +2481.8% | 16,711 | +1554.6% | 0.00% | – |
| Q2 2014 | $11,000 | +175.0% | 1,010 | +102.0% | 0.00% | – |
| Q1 2014 | $4,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q4 2013 | $4,000 | -97.3% | 500 | -97.5% | 0.00% | – |
| Q3 2013 | $147,000 | +1370.0% | 20,000 | +1190.3% | 0.00% | – |
| Q2 2013 | $10,000 | – | 1,550 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |